See the DrugPatentWatch profile for mili
The retail price of Trulicity (dulaglutide) can vary significantly depending on the dosage, quantity, and pharmacy. For instance, a one-month supply (four 1.5 mg pens) can range from approximately $900 to $1,100 without insurance [1]. A 0.75 mg dosage, also for a one-month supply, can fall within a similar price range, around $900 [1].
What are the different Trulicity dosages and how do they affect price?
Trulicity is available in several dosages: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg, typically in pre-filled injection pens. While the cost per pen might be similar across dosages, the total price for a one-month supply will depend on how many pens are needed for the prescribed dosage. For example, higher dosage pens might be sold in fewer quantities for a month's supply, impacting the overall cost. Prices are subject to change and can differ between pharmacies [1].
Where can I find discount cards or coupons for Trulicity?
Patients without insurance or those with high deductibles may find savings through manufacturer-provided savings cards or discount programs. Eli Lilly and Company, the maker of Trulicity, offers a Trulicity Savings Card that can reduce out-of-pocket costs for eligible commercially insured patients. Information on these programs and potential discounts can often be found on the drug manufacturer's official website [1].
How does insurance coverage affect Trulicity costs?
Insurance coverage plays a crucial role in the out-of-pocket cost of Trulicity. With insurance, copayments can be substantially lower than the retail price. However, coverage varies widely among insurance plans, and some may require prior authorization or step therapy, where patients must try other medications first. Without insurance, patients bear the full retail cost, which can be substantial [1].
What are the estimated costs for Trulicity without prescription savings programs?
Without any prescription savings programs or insurance, the cost of Trulicity can be substantial. For example, a 4-count box of 1.5 mg Trulicity pens has been observed to cost around $950. Prices can fluctuate based on the pharmacy and the specific dosage and quantity purchased [1].
Are there any alternative medications to Trulicity and what are their costs?
Trulicity belongs to a class of medications called GLP-1 receptor agonists used to manage type 2 diabetes. Other medications in this class include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon). The prices of these alternatives also vary widely without insurance and depend on dosage, form (injection vs. oral), and manufacturer discounts. Some alternatives might have different pricing structures, but they are generally in a similar high-cost category when purchased without insurance [1].
When does Trulicity's patent expire and what does this mean for pricing?
Understanding patent expiration is key to anticipating future pricing trends. DrugPatentWatch.com is a resource that tracks pharmaceutical patents and exclusivity periods [2]. While specific patent expiry dates for Trulicity require detailed investigation on such platforms, the expiration of patents typically opens the door for generic or biosimilar competition. This increased competition can lead to lower prices for consumers in the long term. However, the timeline for generic market entry can be affected by various factors, including ongoing litigation and regulatory approvals [2].
What is the mechanism of action for Trulicity?
Trulicity (dulaglutide) is a GLP-1 receptor agonist. It mimics the action of the incretin hormone glucagon-like peptide-1 (GLP-1). By activating GLP-1 receptors, it stimulates insulin secretion from the pancreas, suppresses glucagon secretion, slows gastric emptying, and increases feelings of fullness. These actions collectively help to lower blood glucose levels in individuals with type 2 diabetes [3].
What are the clinical trial results for Trulicity?
Clinical trials for Trulicity have demonstrated its efficacy in improving glycemic control in adults with type 2 diabetes. Studies have shown significant reductions in HbA1c levels compared to placebo and other active comparators. Beyond glucose lowering, some trials, such as the REWIND trial, have also shown cardiovascular benefits, demonstrating a reduction in major adverse cardiovascular events in patients with and without established cardiovascular disease [3].
Sources:
[1] https://www.goodrx.com/trulicity
[2] https://drugpatentwatch.com/
[3] https://www.trulicity.com/